442199-11-3

Basic information

• Product Name: 1-Piperidinecarboxylic acid, 4-[(6-chloro-2-pyridinyl)oxy]-, 1,1-dimethylethyl ester
• Synonyms: tert-butyl 4-[(6-chloro-2-pyridyl)oxy]-1-piperidinecarboxylate;tert-butyl 4-((6-chloropyridin-2-yl)oxy)piperidine-1-carboxylate;tert-butyl 4-[(6-chloro-2-pyridinyl)oxy]-1-piperidinecarboxylate
• CAS NO: 442199-11-3
• Molecular Formula: C15H21ClN2O3
• Molecular Weight: 312.79200
• Mol File: 442199-11-3.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 1-Piperidinecarboxylic acid, 4-[(6-chloro-2-pyridinyl)oxy]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperidinecarboxylic acid, 4-[(6-chloro-2-pyridinyl)oxy]-, 1,1-dimethylethyl ester(442199-11-3)
• EPA Substance Registry System: 1-Piperidinecarboxylic acid, 4-[(6-chloro-2-pyridinyl)oxy]-, 1,1-dimethylethyl ester(442199-11-3)

Safety Data

• Hazardous Substances Data: 442199-11-3(Hazardous Substances Data)

Usage

Industry usage

Pharmaceutical industry

Medicinal use

Treatment of erectile dysfunction and pulmonary arterial hypertension

Classification

Phosphodiesterase type 5 inhibitor

Mechanism of action

Blocks the action of a specific enzyme in the body that helps to regulate blood flow

Importance

Plays a crucial role in the treatment of various medical conditions and is a key component in the production of tadalafil.

Upstream product

• 2402-78-0 2,6-dichloropyridine 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 16879-02-0 6-chloro-2-hydroxypyridine 

Downstream Products

• 442198-42-7 (2E)-3-(4-Chlorophenyl)-N-[(1S)-2-[(2-{4-[(6-chloro-2-pyridyl)oxy]-1-piperidinyl}-2-oxoethyl)amino]-2-oxo-1-(2-pyridylmethyl)ethyl]acrylamide 

Relevant articles and documents

BICYCLIC GPR119 MODULATORS

The present invention relates to compounds of Formula (I) that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of GPR119 receptor activity. The invention also relates to the process for preparation of the compounds, pharmaceutical compositions thereof. The invention further relates to methods o f treating, preventing and/or managing diseases, disorders syndromes or conditions associated with the modulation of GPR119 receptor by using either alone or in combinations of Formula (I)

Peptide compounds

The present invention relates to a compound of the formula (I)wherein R1 is benzofuranyl substituted by halogen, or styryl substituted by halogen; R2 is substituted hydroxy, substituted mercapto or substituted sulfonyl; and X is or pharmaceutically acceptable salts thereof. The compound (1) of the present invention and pharmaceutically acceptable salts thereof possess a strong inhibitory activity on the production of nitric oxide (NO), and are useful for prevention and/or treatment of NO-mediated diseases in human being and animals.